<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156330">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818492</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-04</org_study_id>
    <secondary_id>2012-003632-23</secondary_id>
    <nct_id>NCT01818492</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis</brief_title>
  <official_title>A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis Which Has Reactivated.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>7th Framework Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Paul Ehrlich Institute, PEI</authority>
    <authority>Spain: Agencia Espanola de Medicamentos y Productos Sanitarios AEMPS</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and preliminary efficacy of
      a new drug aimed at controlling disease reactivation in patients diagnosed with primary
      haemophagocytic lymphohistiocytosis and having previously shown partial response to current
      recommended treatment. The new drug will be administered on top of a glucocorticosteroid,
      which is usually part of the current recommended treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of NI-0501 in haemophagocytic lymphohistiocytosis</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs
Physical examination
Recording of adverse Events
Routine laboratory assessments</description>
  </primary_outcome>
  <other_outcome>
    <measure>Preliminary efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evolution of clinical signs (such as fever, splenomegaly, central nervous system symptoms) and laboratory parameters (such as complete blood cell count, fibrinogen, serum triglycerides, ferritin, soluble Interleukin-2 receptor levels), which characterize the disease, to assess response and time to response.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Primary Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>NI-0501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NI-0501</intervention_name>
    <arm_group_label>NI-0501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: male and female

          -  Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis

          -  Primary HLH patients who have previously achieved at least partial response to
             conventional induction therapy and who present a reactivation of the disease

          -  Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed
             informed consent

        Exclusion Criteria:

          -  Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven
             rheumatic or neoplastic disease.

          -  Body weight &lt; 3 kg.

          -  Patients treated with biologics within a specific timeframe

          -  Reactivation associated with isolated or multiple acute organ failure(s) (heart, lung
             or kidney) requiring aggressive therapy such as high dose of inotropic drugs,
             circulatory assistance, hemofiltration or haemodialysis, artificial ventilation.

          -  Active infections.

          -  History of malignancy.

          -  Concomitant disease or malformation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristina de Min, MD</last_name>
    <phone>+41-22-593-</phone>
    <phone_ext>5116</phone_ext>
    <email>cdemin@novimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Powell, MD</last_name>
      <phone>302-651-5505</phone>
      <email>Jonathan.Powell@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara A Degar, MD</last_name>
      <phone>617-632-5186</phone>
      <email>Barbara_Degar@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A Degar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jordan, MD</last_name>
      <phone>513-636-7287</phone>
      <email>Michael.Jordan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Allen, MD, PhD</last_name>
      <phone>832-824-4312</phone>
      <email>ceallen@txch.org</email>
    </contact>
    <investigator>
      <last_name>Carl Allen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Holter, MD</last_name>
      <phone>0043 1 40 170 1250</phone>
      <email>wolfgang.holter@stanna.at</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Holter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles University Prague University Hospital Motol - Department of Pediatric Hematology and Oncology</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Sedlacek, MD</last_name>
      <phone>0042 0224436401</phone>
      <email>petr.sedlacek@lfmotol.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Sedlacek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Jurgens, MD</last_name>
      <phone>0049 2518347941</phone>
      <email>jurgh@uni-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Herbert Jurgens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Bambi, MD</last_name>
      <phone>+39 055-5662</phone>
      <phone_ext>991</phone_ext>
      <email>f.bambi@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Franco Bambi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi, MD</last_name>
      <phone>0039_010_5636</phone>
      <phone_ext>715</phone_ext>
      <email>concettamicalizzi@ospedale-gaslini.ge.it</email>
    </contact>
    <investigator>
      <last_name>Concetta Micalizzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Rizzari, MD</last_name>
      <phone>0039_039_233</phone>
      <phone_ext>3513</phone_ext>
      <email>c.rizzari@hsgerardo.org</email>
    </contact>
    <investigator>
      <last_name>Carmelo Rizzari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santobono Pausilipon</name>
      <address>
        <city>Naples</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen De Fusco, MD</last_name>
      <phone>0039_081_2205410</phone>
      <email>carmendefusco@iol.it</email>
    </contact>
    <investigator>
      <last_name>Carmen De Fusco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MariaCaterina Putti, MD</last_name>
      <phone>0039 049 8213535</phone>
      <email>mariacaterina.putti@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Mariacaterina Putti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>0039 06 68592678</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Regina Margherita / S. Anna - Unità di Oncoematologia</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>0039 011 313 5259</phone>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Sanchez de Toledo, MD</last_name>
      <phone>0034 934893093</phone>
      <email>jossanchez@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Jose Sanchez de Toledo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Bilbao</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Itziar Astigarraga, MD</last_name>
      <phone>0034 946006357</phone>
      <email>itziar.astigarraga@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Itziar Astigarraga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat (Barcelona)</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laia Alsina Manrique de Lara, MD</last_name>
      <phone>0034 932804000</phone>
      <phone_ext>3330</phone_ext>
      <email>lalsina@hsjdbcn.org</email>
    </contact>
    <investigator>
      <last_name>Laia Alsina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Lassaletta Atienza, MD</last_name>
      <phone>0034 915035938</phone>
      <email>lassaalvaro@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alvaro Lassaletta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
